Direct oral anticoagulants in atrial fibrillation

• Autores: D. Gómez Herrero, Francisco Javier Carrera Hueso, Jaime E. Poquet Jornet, R. Vila Miralles, Auxiliadora Ramón Barrios, R. Sanjuan Cerveró
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 20, Nº. 2, 2018, págs. 99-106
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Oral anticoagulants are recommended for the prevention of stroke in patients with non-valvular atrial fibrillation. Vitamin K antagonists (VKA) have been used for decades for the treatment and prophylaxis of thromboembolic events. However the direct oral anticoagulants (DOAC), the direct thrombin inhibitor dabigatran and the factor Xa activated inhibitor, apixaban, rivaroxaban and edoxaban, have shown superior safety and efficacy in clinical trials, and are presented as a safe, effective and simple alternative to fixed dose administered. Despite the lack of precise laboratory tests, the degree of anticoagulation cannot be quantified, and are influenced by the changes in drug concentrations during the dosing interval, and also the potential drug interactions and lack of antidote, make the selection of appropriate anticoagulant a clinical challenge